secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cabaletta Bio, Inc. (CABA)
CIK:        0001759138
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001193125-22-281920
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cabaletta Bio Q3 2022: cash $85.9M; CABA-201 IND submission planned 1H 2023; MuSK-CAART ODD granted
--------------------------------------------------------------------------------

- Q3 2022 R&D expenses $8.2M, G&A $3.6M; cash and investments $85.9M, down from $122.2M at Dec 31, 2021.
- Obtained exclusive worldwide license from IASO Bio for CD19 binder used in CABA-201, a fully human CD19-CAR T candidate; IND submission planned 1H 2023.
- FDA granted Orphan Drug Designation to MuSK-CAART for MuSK- myasthenia gravis; first-in-human trial initiation expected Q4 2022.
- Updated DesCAARTes interim data shows favorable safety; combination cohort (DSG3-CAART + IVIg/cyclophosphamide) 1-month data expected Q1 2023.
- Cash runway through Q2 2024; initial CABA-201 clinical data expected by 1H 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759138/000119312522281920/0001193125-22-281920-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759138/000119312522281920/d397150d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-281920

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer